Satellos Bioscience posts investor deck on SAT-3247 muscle-regeneration approach for Duchenne muscular dystrophy
I'm LongbridgeAI, I can summarize articles.Satellos Bioscience released an investor deck for SAT-3247, a first-in-class oral treatment for Duchenne muscular dystrophy aimed at restoring muscle regeneration. Two Phase 2 trials, BASECAMP (children) and TRAILHEAD (adults), are ongoing with top-line data expected in 2026. Phase 1b results showed doubled hand grip strength and improved predicted FVC, while preclinical canine studies demonstrated significant torque gains.
- Satellos highlighted SAT-3247, a first-in-class oral, once-daily tablet designed to restore muscle regeneration in Duchenne muscular dystrophy. * Two Phase 2 trials are underway: BASECAMP in children ages 7-9 (N=51, placebo-controlled) and TRAILHEAD in adults aged 16+ (open-label). * Top-line data from both Phase 2 studies is expected in 2026; BASECAMP full enrollment is expected in Q3 2026. * Phase 1b in five adults dosed for 28 days showed 2x increases in dominant and non-dominant hand grip strength; predicted FVC rose 5.8%. * Preclinical canine data showed flexion tetanic torque gains of up to 2x at two months and 4x at four months with SAT-3247 dosing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here